Post Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In Patients With Hemophilia B
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
To provide safety and effectiveness information of BeneFIX during the post-marketing period
as required by Korea FDA regulations, to identify any potential drug related treatment
factors in Korean population including:
1) Unknown adverse reactions, especially serious adverse reactions; 2) Changes in the
incidences of adverse reactions under the routine drug uses.
3) Factors that may affect the safety of the drug 4) Factors that may affect the
effectiveness of the drug